Floatz logo

Cyclophosphamide

Ureteral Neoplasms

Eli Lilly and CompanySmall moleculePhase 1/2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Ureteral Neoplasms cohort.

Asset / SponsorPhaseRating
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Eli Lilly and Company
Phase 2BB
Carboplatin
Astellas Pharma Global Development, Inc.
Phase 2BB
Carotuximab
National Cancer Institute (NCI)
Phase 2B
Pembrolizumab
Eli Lilly and Company
Phase 1/2CCC
Epirubicin
Eli Lilly and Company
Phase 1/2CCC
CIS-DIAMMINEDICHLOROPLATINUM II
Astellas Pharma Global Development, Inc.
Phase 1/2CCC
Loxo-435
Eli Lilly and Company
Phase 1CC

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →